PMID

Data

Article Title

Organization

Exploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors.

Indiana University School of Medicine

Therapeutic potential of targeting the oncogenic SHP2 phosphatase.

Indiana University School of Medicine

A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases.

Indiana University School of Medicine

Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors.

Eli Lilly

Design and synthesis of potent, non-peptidic inhibitors of HPTPbeta.

Procter & Gamble Pharmaceuticals

Inhibition of Low Molecular Weight Protein Tyrosine Phosphatase by an Induced-Fit Mechanism.

Purdue University

Highly Potent and Selective

Purdue University

Synthesis and PTP Inhibitory Activity of Illudalic Acid and Its Methyl Ether, with Insights into Selectivity for LAR PTP over Other Tyrosine Phosphatases under Physiologically Relevant Conditions.

University of Utah

Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)

Indiana University Research and Technology

Inhibitors of protein tyrosine phosphatases

Indiana University Research and Technology